Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Adaptimmune announces that study continues to report encouraging response rates, safety and proof of mechanism.

Interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells have been released. The study Chair presented these updated results today at the annual meeting of the American Society of Hematology (ASH). 

The clinical trial was designed as a single arm open label study where patients are given standard of care (autologous stem cell transplant). This is followed by infusion of a patient’s own T cells that have been genetically engineered to carry receptors that help the T cells recognize and attack tumors, while sparing healthy tissue. 

The objectives for the study are to evaluate the safety, bioactivity and anti-tumor effect of infusion of patients’ own T cells that have been genetically modified to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen (protein) known as a cancer testis antigen (CT antigen). The target CT antigens in the study are NY-ESO-1 and LAGE-1. Anti-tumor responses are reported as best response by day 100 following the transplant and T cell infusion. 

The initial six patient phase was completed in 2012 and based on encouraging preliminary results announced at ASH last December, the study was extended to a target enrollment of 26 patients. To date, 21 patients have been enrolled. 20 patients have received engineered T cells and have been assessed at day 100 for tumor responses to the treatment. 19 patients have reached a minimum of six month follow-up and 15 patients have reached one year follow-up. 

After one year, patients are followed for disease status quarterly, and progression free and overall survival will be collected as the study follow-up matures. Patients are also monitored no less than bi-annually for safety and correlatives specific to the engineered T cells. 

Multiple myeloma is a hematologic cancer localized to the bone marrow and is currently incurable in most patients. With standard therapy, long-term response rates are low and the median survival for patients with this disease is three to five years. 

The clinical study focuses on this unmet medical need and includes patients who have received prior treatment for their myeloma or who have disease considered to be high risk, who are eligible for an autologous stem cell transplant (auto-SCT), and whose tumor expresses NY-ESO and/or LAGE-1. Auto-SCT is the transplant of a patient’s own stem cells, which is a standard of care for treatment of multiple myeloma in the U.S. Infusion of the gene modified T cells occurs two days following auto SCT. 2 

Dr. Aaron Rapoport, the Chair of the clinical study, presented abstract 766 entitled “Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR in Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated with Encouraging Post Auto-SCT Responses”. 

He reports that infusions of engineered T cells have been well tolerated. The overall best response rate at 100 days is 77%. This rate is encouraging in these patients, of whom approximately 50% have high risk disease, 25% have received prior transplant, and NY-ESO expression is associated with poor prognosis. 

Of the 20 patients treated to date, 13 have ongoing responses, and seven have progressed. In cases of disease progression, a concomitant loss or reduction of engineered T cells, or a loss of antigen positivity on recurring tumor has been observed. Consequently, the protocol has been modified to allow for additional infusions without concomitant transplant, provided the patient’s tumor continues to express target antigen. 

“The clinical responses seen in our patients are encouraging and are generally better than I expected from transplant alone,” says Dr. Rapoport, the Gary Jobson Professor in Medical Oncology at the University of Maryland School of Medicine and Associate Director of the Blood and Marrow Transplant Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. “I look forward to making this technology available to patients outside of the transplant setting.” 

Enrollment is nearly completed and a final study analysis in planned to start in late 2014. Interim safety and response data presented at the ASH conference is under preparation for publication in the first half of next year. 

“This study has provided us with important insights into the activity of NY-ESO T cells,” said Mr. James Noble, Chief Executive Officer of Adaptimmune. “It has been a privilege to work with this translational team and we are encouraged by progress to date on this study and our studies in solid tumor indications.” 

Additional study details and contact information for patients interested in finding out more about participation can be found at, under trial identifier number NCT01352286. 

The study was originally developed by Dr. Carl H. June at the University of Pennsylvania (UPenn) Abramson Cancer Center and Dr. Rapoport. Dr. Rapoport is the lead clinical investigator at the University of Maryland and protocol Chair. Dr. Edward Stadtmauer is the lead clinical investigator at the UPenn Abramson Cancer Center, and Dr. Dan Vogl is a sub-investigator at UPenn. Dr. Michael Kalos led correlative studies at UPenn during his tenure as Director of the Translational and Correlative Sciences Laboratory (TCSL) at UPenn (now at Eli Lilly), and Dr. Simon Lacy is completing these studies at the TCSL on his behalf. Initially, Dr. June served as the regulatory sponsor (FDA representative) for the study and T cell manufacturing was performed at the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania directed by Dr. Bruce Levine. In April 2013, following the Novartis engagement of UPenn for CD19 engineered T cell therapy in CLL and ALL, Adaptimmune assumed the sponsorship and T cell manufacturing roles for this study. Adaptimmune is also the financial sponsor for the study and owns the T cell receptor technology. 3 

Adaptimmune has also opened a new 10 patient pilot study, designed to evaluate the safety and anti-tumor effects of the engineered T cells without transplant. This trial is now enrolling at the University of Maryland in Baltimore, Maryland, and the City of Hope in Duarte, California. 

Additional study details and contact information for patients interested in finding out more about participation can be found at, under trial identifier number NCT01892293. 

Other trials in ovarian cancer, melanoma and synovial sarcoma are ongoing in the U.S. and can be found on

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune Announces New Research and Development Facility in Oxfordshire
‘Enterprise Zone’ building will house company’s expanding R&D operation.
Wednesday, October 07, 2015
Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma
The company have announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.
Friday, September 04, 2015
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Tuesday, July 21, 2015
Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
Lawrence M. Alleva will join the Board as an independent, non-executive director.
Wednesday, March 11, 2015
Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer.
Wednesday, March 04, 2015
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Friday, October 17, 2014
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
Company has created T-cell receptors which are deployed to target NY-ESO-1.
Tuesday, September 23, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund
The prestigious award supports Adaptimmune’s clinical pipeline expansion.
Tuesday, March 25, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Adaptimmune Appoints Chairman of the Board
Dr Jonathan Knowles has been appointed as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 21, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Thursday, January 24, 2013
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos